Luca Boscolo Bielo (@boscololuca_) 's Twitter Profile
Luca Boscolo Bielo

@boscololuca_

ID: 1451191307758493714

calendar_today21-10-2021 14:19:12

13 Tweet

112 Followers

80 Following

Edoardo Crimini MD (@criminimd) 's Twitter Profile Photo

Such a honor to attend ESMO TAT 2024 with my fantastic mentors, G Curigliano MD PhD and Dr. Meric-Bernstam, TAT Honorary Award recipient for her contribution to precision oncology. Congrats also to Luca Boscolo Bielo for the best abstract award in the Molecular profiling applications section!

Such a honor to attend ESMO TAT 2024 with my fantastic mentors, <a href="/curijoey/">G Curigliano MD PhD</a> and Dr. Meric-Bernstam, TAT Honorary Award recipient for her contribution to precision oncology. Congrats also to <a href="/BoscoloLuca_/">Luca Boscolo Bielo</a> for the best abstract award in the Molecular profiling applications section!
Luca Boscolo Bielo (@boscololuca_) 's Twitter Profile Photo

I fully endorse the nomination of Giuseppe Curigliano for the next esmo presidency. A visionary, a leader, but most importantly a mentor for a countless number of young medical oncologists. Vote for him for a brighter future. ESMO - Eur. Oncology G Curigliano MD PhD

Ben Westphalen (@benwestphalen) 's Twitter Profile Photo

Kicking of anew #OpenAccess new series in ESMO - Eur. Oncology Gastrointestinal #Oncology —> Exploring the pathway  🔎 Thanks to Lena Weiss & Luca Boscolo Bielo for doing the heavy lifting! #PrecisionMedicine OncoAlert 🚨Vivek Subbiah, MD esmogastro.org/article/S2949-…

ESMO Open (@esmo_open) 's Twitter Profile Photo

Retrospective analysis of MTB impact on the care of patients with GI tumors at IEO just published in ESMO Open. Among 192 patients discussed at the MTB, 31 (17.7%) were recommended molecularly guided treatment options, experiencing longer rwPFS. esmoopen.com/article/S2059-…

Retrospective analysis of MTB impact on the care of patients with GI tumors at <a href="/IEOufficiale/">IEO</a> just published in <a href="/ESMO_Open/">ESMO Open</a>. Among 192 patients discussed at the MTB, 31 (17.7%) were recommended molecularly guided treatment options, experiencing longer rwPFS. esmoopen.com/article/S2059-…